Relypsa Inc

Relypsa, Inc. is a privately-held, clinical-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the treatment of hyperkalemia. Five clinical trials involving RLY5016 have been successfully...